Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

2(66.7%)

Phase 2

1(33.3%)

3Total

N/A(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT04379258Completed

Analysis of Mortality of Critically Ill Patients With COVID-19

Role: collaborator

NCT04380818Not ApplicableUnknown

Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19

Role: collaborator

NCT03721731Completed

A Post-Market Surveillance Study of Using the g-Cath EZ for Treating Obesity

Role: collaborator

NCT03611504Completed

Hemospray in Gastrointestinal Bleeding: A Real-life Multicenter Cohort

Role: collaborator

NCT01990430Not ApplicableUnknown

Behavioural Changes in Breast Cancer Patients

Role: collaborator

NCT01321775Phase 2Unknown

Bevacizumab and Trastuzumab With Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer

Role: lead

All 6 trials loaded